Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial

  • Ramez N. Eskander
  • , Michael W. Sill
  • , Lindsey Beffa
  • , Richard G. Moore
  • , Joanie M. Hope
  • , Fernanda B. Musa
  • , Robert S. Mannel
  • , Mark S. Shahin
  • , Guilherme H. Cantuaria
  • , Eugenia Girda
  • , Elizabeth Lokich
  • , Juraj Kavecansky
  • , Charles A. Leath
  • , Lilian T. Gien
  • , Emily M. Hinchcliff
  • , Shashikant B. Lele
  • , Lisa M. Landrum
  • , Floor Backes
  • , Roisin E. O’Cearbhaill
  • , Tareq Al Baghdadi
    • Emily K. Hill, Premal H. Thaker, Veena S. John, Stephen Welch, Amanda N. Fader, Matthew A. Powell, Carol Aghajanian

Research output: Contribution to journal › Article › peer-review

28   Link opens in a new tab Scopus citations

Fingerprint

Dive into the research topics of 'Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial'. Together they form a unique fingerprint.
Sort by

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science